Using oxygen sensors to improve cancer treatment
Official title: Minimally invasive quantitative tissue oxygen sensors to personalize cancer care
Funded at Stratagen Bio, INC. · NIH-10698650 · Data updated 2026-11-12
This study is testing a new, easy-to-use oxygen sensor that can be placed in tumors to help doctors better understand oxygen levels, which could lead to more personalized and effective treatments for cancers like breast, cervical, and prostate cancer.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stratagen Bio, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | September 14, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $399,888 |
| NIH project number | 1R43CA281444-01 |
| Project ID | NIH-10698650 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with hypoxic tumors, particularly those with breast, cervical, or prostate cancer.
✕Less likely to help
Patients with non-hypoxic tumors or those not undergoing radiation therapy may not benefit from this research.
What this research studies
This research investigates a new type of minimally invasive oxygen sensor designed to measure oxygen levels in tumors, which can help personalize cancer treatment. By providing real-time, quantitative data on tumor oxygenation, the sensor aims to enhance the effectiveness of radiation therapy, particularly for cancers like breast, cervical, and prostate cancer. The sensor is made from silicone, allowing for easy insertion and long-term monitoring without significant invasiveness. It utilizes MRI technology to ensure precise spatial context for each measurement, which is crucial for tailoring treatment plans.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by overcoming resistance caused by low oxygen levels in tumors.
How similar studies have gone: Previous research has shown promise in using oxygen sensors for cancer treatment, but this specific approach is innovative and largely untested.
Where this research is happening
-
Stratagen Bio, INC.
Cambridge, United States Active
Researchers
- Principal investigator: Ekchian, Gregory — Stratagen Bio, INC.
- Study coordinator: Ekchian, Gregory
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.